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Endovascular coils as lung tumour markers
in real-time tumour tracking stereotactic
radiotherapy: preliminary results
Abstract To evaluate the use of
endovascular coils as markers for
respiratory motion correction during
high-dose stereotactic radiotherapy
with the CyberKnife, an image-guided
linear accelerator mounted on a ro-
botic arm. Endovascular platinum
embolisation coils were used to mark
intrapulmonary lesions. The coils
were placed in subsegmental pulmo-
nary artery branches in close
proximity to the target tumour. This
procedure was attempted in 25
patients who were considered unsuit-
able candidates for standard transtho-
racic percutaneous insertion. Vascular
coils (n=87) were succesfully inserted
in 23 of 25 patients. Only minor
complications were observed:
haemoptysis during the procedure
(one patient), development of pleural
pain and fever on the day of procedure
(one patient), and development of
small infiltrative changes distal to the
vascular coil (five patients). Fifty-
seven coils (66% of total inserted
number) could be used as tumour
markers for delivery of biologically
highly effective radiation doses
with automated tracking during
CyberKnife radiotherapy.
Endovascular markers are safe
and allow high-dose radiotherapy
of lung tumours with CyberKnife,
also in patients who are unsuitable
candidates for standard transthoracic
percutaneous marker insertion.
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Introduction
Conventional radiotherapy for early stage non-small cell
lung cancer (NSCLC) has poor clinical outcome [1]. New
radiotherapy techniques have been developed to deliver a
higher radiation dose to the lung tumour while sparing
adjacent normal tissue [2–6]. Common to these new
regimens is the control for respiratory motion in combina-
tion with the use of a stereotactic coordinate system [7, 8].
Target localisation can be further improved by the insertion
of small metallic markers into the lung tumour, which are
automatically detected by the image guidance of tumour
tracking radiotherapy systems (TTRS) [8] or internal
gating systems [6]. Both marker-based treatment systems
enable a considerable reduction of the safety margin to
avoid a geometric miss, resulting from tumour motion
outside the radiation beam. This limits the volume of
nearby healthy tissues that will be irradiated, reducing the
toxicity of the treatment. As a result, high biologic effective
radiation doses shown to obtain local control rates on the
order of 90% in stage I NSCLC can then be safely
administered [9, 10].
The standard technique of marker insertion for tumour
tracking is a direct percutaneous transthoracic puncture [8].
The insertion of a marker inside the lung tumour was
shown to enable an accurate three-dimensional (3D) target
localisation during the respiratory motion [6].
However, not all lung tumours (e.g., cavernous tumours
or small, lesions without clear contours) are suitable for
transthoracic percutaneous marker placement. Further-
more, the 22–45% risk of pneumothorax after transthoracic
marker placement may be unacceptably high for some of
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3015 GD Rotterdam, The Netherlandsthis generally frail patient population due to severe cardio-
pulmonary co-morbidity [8, 11–13]. Thus, many patients
with NSCLC who might potentially benefit from curative
radiotherapy currently cannot undergo such high-dose
radiotherapy treatment because of the limitations inherent
to marker placement by transthoracic puncture.
Therefore, we explored the use of vascular embolisation
coils, positioned in small subsegmental pulmonary artery
branches surrounding the tumour, as markers for tumour
tracking. Endovascular marker placement would be an
achievable alternative also in tumours difficult to reach for
transthoracic puncture. This would also eliminate the risk
of pneumothorax. Here, we report our initial results on the
feasibility,effectiveness andcomplications of endovascular
coils, as markers for the Synchrony™ [14], the respiratory
tumour tracking system of the CyberKnife (Accuray,
Sunnyvale, CA).
Materials and methods
Patients
From May 2005 to November 2006, 50 patients with a lung
tumour were referred for frameless motion-corrected
stereotactic radiotherapy with the Synchrony™ system of
the CyberKnife. In 25 patients, metallic markers for tumour
tracking were inserted using direct transthoracic puncture.
In 25other patients (18 male, 7female), direct transthoracic
puncture was considered not feasible or too risky due to:
possible major clinical consequences of a pneumothorax
for six patients (history of pneumonectomy (2 patients),
bilobectomy (two, including one patient with a lesion
without clear contours), lobectomy (one) and one oxygen
dependent patient), a major risk to develop pneumothorax
(two patients with one lesion in each lung, including one
patient with a cavernous tumour; two patients with two
lesions in the same lung), the combination of advanced age
and/or cardiopulmonary toxicity (15 patients). The median
age of these 25 patients was 79 years (range, 28–89).
Twenty patients had primary NSCLC, which was biopsy
proven in 12. Five patients were treated for metastatic lung
disease: one of cervical carcinoma (two lesions, left-sided
and right-sided), two of rectal carcinoma (including one
patient with one lesion in each lung), one of malignant
melanoma (two lesions in the left lung) and one of a breast
carcinoma (two lesions in the right lung). Table 1 shows the
diameter, number and localisation of the lung lesion(s). The
Charlson Comorbidity Score [15], assessing the comorbid-
ity of a given patient by accounting for several health
disorders, is also shown in Table 1. Approval from the
Ethics Committee was obtained for the use of vascular
embolisation coils as marker for lung tumours, and all
patients gave informed consent prior to the insertion of
embolisation coils.
Technique of endovascular marker insertion
The patient was installed in the supine position, and the
procedure was performed in the interventional suite.
A 7-F pulmonary angiography catheter (Grollman-type
angled pigtail) was inserted through the femoral vein
(although both sides can be used, the right femoral vein
was habitually punctured) and positioned in the left or right
main pulmonary artery under ECG monitoring (Fig. 1).
Over a .035” guide wire, the catheter was exchanged for a
5-F angled tipped general-purpose catheter with a single
end hole. The catheter was advanced over the guide wire
into one of the subsegmental pulmonary artery branches in
the vicinity of the lung tumour. Larger but not smaller
tumours could be well seen with fluoroscopy during the
procedure. The position of smaller tumours was inferred
from the pre-procedural CT examination of the lungs, and
catheter placement was then based on segmental anatomy
of the pulmonary arteries. When in the desired position, the
catheter was wedged into a small subsegmental pulmonary
Table 1 Charlson Comorbidity Score and tumour characteristics
Patient number Diameter of
nodule(s)
(mm)
Number of
nodules, lung side
Charlson
Comorbidity
Score
13 6 1 , R3
2 31/28 2, L 6
3 32 1,R 3
4 44 1,R 5
5 27 1,R 8
6 23/27 1 L; 1 R 6
72 3 1 , R7
83 4 1 , L1
92 0 1 , L3
10 50 1, R 1
11 32 1, R 1
12 24 1, L 3
13 40 1, R 2
14 30 1, R 5
15 29 1, L 3
16 55 1, R 1
17 26 1, R 2
18 17/20 2, R 6
19 16/6 1 L, 1 R 3
20 40 1, R 5
21 30 1, R 2
22 11 1, R 3
23 24 1, L 4
24 15 1, L 2
25 29 1,R 3
*Failure to insert coil, L = left lung, R = right lung
1570artery branch and a 3–4-mm tapered platinum embolisation
coil was placed (Tornado Embolization coils, Cook,
Bloomington, IN). Platinum coils were used because of
their high radio-opacity. Ideally, three coils were placed.
After the procedure, we recorded any clinical symptoms
suggestive of immediate pulmonary complications. After
an average period of 7 days (range, 2–19 days), a non-
contrast-enhanced four-dimensional multislice planning
CT (4-D CT) examination was performed, which was
evaluated for possible complications of coil placement. The
4-D CT was also used to appreciate the extent of
synchronous motion of the tumour with coils on a given
distance.
Complications were classified according to the Society
of Interventional Radiology (SIR) reporting standards [16].
The SIR standards of the practice committee classifies the
complications by outcome: type A complications are minor
complications that require no therapy and have no
consequence; type B complications are minor complica-
tions requiring nominal therapy, including overnight
admission, for observation only and have no consequence;
type C complications are major complications requiring
therapy and include minor hospitalization (< 48 h); type D
complications are major complications that require major
therapy, causing an unplanned increase in level of care, and
include a prolonged hospitalization (>48 h); type E
complications are major complications resulting in perma-
nent adverse sequelae, and type F complications result in
death of the patient.
CyberKnife
The CyberKnife is a frameless image-guided radiotherapy
system. The 6-MV linear accelerator is mounted on a
robotic arm possessing six degrees of motion freedom. The
CyberKnife therapy unit is equipped with an image-
guidance system that consists of two kV X-ray tubes
attached to the ceiling of the treatment room and a pair of
orthogonally positioned flat-panel imagers mounted on the
floor. A marker extraction algorithm automatically detects
the position of the markers in the X-ray images. Basically,
the algorithm searches for areas with high contrast in both
images that could originate from a single marker. These
areas are candidate markers. On the basis of the expected
characteristics of the markers and their expected relative
positions from the planning CT, the algorithm determines
which candidates are true markers and reconstructs the
marker locations in 3D. Finally, the 3D marker locations
are registered to the marker locations that were determined
in the planning CT to obtain the translations and rotations.
Although one marker is sufficient to reduce translational
setup errors of the target [17], three markers were required
to distinguish marker migration from true tumour motion.
As long as the three markers do not migrate in the same
direction to the same extent, their migration can be detected
by the change in the mutual distance between the markers.
The probability that the three markers would migrate an
identical distance and direction may be considered
sufficiently small to warrant the use of this three marker
method for the detection of marker migration.
The Synchrony™ is the respiratory tumour tracking
system of the CyberKnife. The system automatically
compensates for the tumour motion by continuously
adjusting the position of the beam. The actual motion of
the linear accelerator is determined by a correspondence
model that relates the respiratory signal, registered by light-
emitting diodes placed on the skin, with the internal
metallic markers that are localised by the kV X-ray system.
The correspondence model is built at the start of the
treatment by acquiring kV X-ray images at different phases
of the breathing cycle. During the treatment this model is
continuously updated by acquiring X-ray images every 3 to
5 min.
Results
Coil placement
Endovascular coils (n=87) were succesfully inserted in 23
of 25 patients in whom the procedure was attempted. A
median number of 3 coils for each tumour was inserted
(range, 1–5). Table 2 depicts the number of coils for each
nodule and the total number of coils for each patient. Coils
could also be safely inserted in the two patients with a
lesion in each lung as well as in one patient with a medical
history of pneumonectomy. In five cases the ideal number
of three coils was not inserted due to: haemoptysis during
the procedure after insertion of the 2nd coil (n=1), a
centrally located tumour difficult to access (n=2), long
duration of the procedure and fatigue of the patient (n=2).
Fig. 1 A pulmonary arterial catheter used to place a coil. The
inserted coil is indicated by the arrow: 179×179 mm (96× 96 DPI)
1571These last two patients included a patient in whom two
tumours were marked. In this patient, the procedure was
halted after inserting the fifth coil, that is, the second coil
for the second tumour.
The procedure time was on average approximately 60
min. All the interventions, including also the patients with
multiple lesions, could be performed at once.
The procedure failed in two patients. Here, it proved
difficult to negotiate the angiography catheter through the
pulmonary valve also whenever the Grollman catheter had
been exchanged for a balloon-tipped flow-guided catheter.
Catheter manipulation in the right ventricle induced
ventricular arrhythmias, which was the reason to terminate
the procedure. In both patients, we chose to resort to CT-
guided transthoracic puncture despite the anticipated risk
of pneumothorax rather than proceeding with the endo-
vascular approach and increase the complications risk
angiographically by using full narcosis, more extensive
protection against arrhythmia and more sophisticated
angiography devices including guiding catheters. Trans-
thoracic marker placement was successful in both patients,
but resulted in the development of a small pneumothorax in
one case.
Complications
There were no immediate procedure-related complications
except for one patient who had limited haemoptysis (type
A complication), probably caused by wedging the catheter
too forcefully in the pulmonary artery end branches during
placement of the second coil. The procedure was stopped
and the haemoptysis resolved within 10 min without
ensuing clinical sequelae. One other patient, who had two
lung metastases from cervical cancer marked, developed
chest pain and fever suggestive for pulmonary infarction,
on the day of coil insertion (type C complication). The
patient was treated with standard analgetics and was
admitted more than 2 days in the hospital to exclude other
complications such as pneumonia or pulmonary embolism.
The pain was probably pleuritic because two coils were
placed against the visceral pleura and caused pleuritic
friction and inflammation. All the other patients were
discharged from the day-care facilities after a 2-h post-
procedural observational period.
During the interval between the coil insertion and the
start of the CyberKnife radiotherapy (average 15 days,
range, 7–29), none of the patients reported (an increase of)
dyspnea or fever, except the single patient with type C
complication. The radiation planning CT scan of the lungs
showed no procedure-related abnormalities in 18 of 23
patients. In five patients there were small infiltrative
changes distal to one of the coils suggestive for small areas
of pulmonary infarction (type A complication).
Accuracy of vascular coils as tumour markers
All patients could be successfully treated with the Cyber-
Knife, based on the recognition of minimally one marker
per lesion. Of the 87 coils initially placed, 57 were used as
tumour markers for automated tracking during CyberKnife
radiotherapy. Coils that were deemed unsuitable markers
(see below) were not used by the human operator during
treatment.
Twenty-four coils were not used as markers because they
did not complete their winding and thus did not have a
completely rounded shape. Six coils were disabled based
on a distance judged to be too large (range, 56–123 mm) to
guarantee a similar motion of the coils as the tumour. The
median distance between all the inserted coils and the
tumour border was 18 mm (range, 0–123 mm). Eighteen
coils (21%) were directly abutting the tumour. In one
patient, none of the coils was in an acceptable position. In
retrospect, this was due to erroneous placement of coils in
an entirely wrong position based on imaging during
Table 2 Number of coils inserted per nodule and per patient
Patient number Coil per nodule Total coils inserted
15 5
23 6
32 2
44 4
53 3
6 2 R, 3 L 5
7* *
8* *
92 2
10 4 4
11 4 4
12 3 3
13 4 4
14 4 4
15 3 3
16 3 3
17 3 3
18 2, 3 5
19 2 R, 1 L 3
20 5 5
21 4 4
22 3 3
23 4 4
24 3 3
25 5 5
*Failure to insert coil, R = right lung, L = left lung.
1572placement in the anterior-posterior view only. In this
patient, satisfactory coil position was achieved in a second
angiographic procedure (not counted in this analysis as an
index procedure).
It is of note that all inserted coils were detected during
planning CT and showed no migration, which means the
coils were in a stable, fixed position, during the interval
between the planning CT and the completion of treatment,
which was partitioned over the course of several days.
Discussion
Our results show that endovascular coils can be used as
reliable markers for automated tumour tracking during
high-dose radiotherapy for lung tumours with the Cyber-
Knife. Markers are placed in the interventional radiology
suite by using standard, off-the-shelf angiography equip-
ment and embolisation coils and by using local anaesthesia
only. The procedure is well tolerated, safe and may be
performed on an outpatient basis. After placement, the coils
remain in a stable position and do not migrate as these are
wedged in small pulmonary artery branches.
The endovascular route, therefore, is a valuable alter-
native to the standard method of marker placement by
percutaneous transthoracic puncture. The percutaneous
method, on the other hand, is associated with a 22–45%
risk of pneumothorax, which requires a chest tube insertion
in 27% of the patients with obstructive lung disease, a
particularly frequent disease in this patient population [8,
11–13].
Also, the endovascular approach is feasible whenever
transthoracic puncture is difficult or not possible whenever
the tumour mass is not well defined (e.g., cavernous
tumours, Fig. 2) or whenever the lesion is in a hard to reach
lung area by direct puncture. By also applying endovas-
cular coils as possible tumour markers, many more patients
with lung tumours can now be treated with CyberKnife
radiotherapy. This enables the administration of high
radiation doses, reported to offer excellent clinical results
similar to radical surgery for early stage NSCLC [9, 10,
18]. Although not specifically adressed in this report, we
may expect the use of embolisation coils for marking lung
tumours to be of benefit for every radiotherapy system
using image guidance to detect markers in order to improve
the target localisation.
We did not encounter clinically relevant complications
after endovascular coil placement. One patient experienced
an episode of transient pleural pain, one patient had short-
lived haemoptysis during coil placement, and in two
patients we saw clinically silent CT findings suggestive of
small pulmonary infarction. This was in accordance with
the anticipated complication rate based on previous
experience with coil placement in the pulmonary arteries
for other indications, notably, pulmonary arteriovenous
malformations. Based on this, one would expect to
encounter pulmonary infarction in 6%, pleuritic chest
pain in 33% and groin haematoma in 3% [19].
Another alternative method for marker placement is the
endobronchial placement using video flexible bronchos-
copy with a modified transbronchial needle aspiration. The
rationale to develop this method was the reduction of the
risk of pneumothorax. However, bronchoscopic marker
placement is performed under general anaesthesia (44%) or
conscious sedation (56%) [20].
While transcutaneously placed Visicoil gold localisation
markers (RadioMedCorp., Tyngsboro, MA) were shown to
be stable within tumours throughout the treatment duration
[21], markers placed under bronchoscopy guidance tend to
have less stable fixation. In 3 out of 6 central lung lesions
and 3 out of 41 peripheral lesions, Shirato et al.
encountered a dropping of the marker out of the lesion
[22]. Another study reported that 21% of the inserted
markers could not be detected on the planning CT scan
made at 0–5 days after insertion and probably were
coughed up [23]. Furthermore, the variation in the position
of bronchoscopically implanted markers exceeded 2 mm in
9% of the treatment sessions, necessitating more frequent
reexamination with CT scanning. In our study population,
no gross migration was observed between the planning CT
and during treatment delivery period.
Radiofrequency ablation (RFA) is another treatment
recently investigated in the care of medically inoperable
lung cancer and was shown to obtain promising results.
Simon et al. reported 3-year local control rates of 57% and
25% for T1 and T2 NSCLC tumours, respectively [24].
Fig. 2 Patient with two lung metastases (left and right sided) from a
cervical carcinoma. Transthoracic marker insertion in the right
cavernous lesion is not feasible. Furthermore, transthoracic place-
ment in both lesions would be related to a major risk for
pneumothorax. After endovascular marker placement (coils are
indicated by an arrow), both lesions could be treated with
CyberKnife. 98×83 mm (96×96 DPI)
1573The 36% overall 3-year survival rate for stage I NSCLC
was comparable to those obtained with standard external
beam radiation therapy as reported in the review of Qiao et
al [25]. The report of Simon highlighted the role of tumour
size in the prediction of the local tumour progression rate of
tumours smaller than 3 cm being more effectively treated
with RFA than larger tumours. This observation confirmed
the encouraging results of previous reports showing
complete tumour necrosis in 69%–100% in the tumours
smaller than 3 cm [26, 27]. However, although these results
are very promising, these appear to be inferior to the local
control rates on the order of 90% obtained in stage I
NSCLC with high-dose stereotactic radiotherapy [10].
Radiofrequency ablation was also shown by Simon et al.
[24] to have an acceptable toxicity profile in patients who
refused or who were not candidates for surgery with an
overall pneumothorax rate of 28% with 10% requiring a
chest tube insertion. Of concern is the procedure-specific
30-day mortality rate of 2.6% (4 of 153 patients). Of note,
two of the patients with procedure-related deaths had
previously undergone a pneumonectomy. De Baere et al.
reported a pneumothorax rate of 54% with 9% requiring a
chest tube [28]. Similar morbidity data were reported in
other RF ablation reports [29, 30]. Randomised trials are
required to accurately determine the place of radio-
frequency ablation in the treatment of medically inoperable
NSCLC patients.
Some limitations of our results need further attention. In
this preliminary study we used standard, commercially
availableplatinumembolisationcoilsofataperedshapewith
graduallyincreasingdiameteroftheindividualcoilwindings
from 3 to 4 mm. These proved to be useful, but not ideal
markers for the CyberKnife. In 24 of 87 cases (27%) the 4-
mm diameter windings proved too big for the small
subsegmental artery branches in which the angiography
catheter was wedged. These windings remained stretched
(non-coiling), which rendered these coils unsuitable for
automated tracking (Fig. 3). Obviously, smaller winding
coils are needed, but still on a .035” wire-based platform to
ensure adequate radio-opacity and for ease of delivery
through standard angiography catheters. As a further
advantage,smallercoilsmayallowevenmoredistalinsertion
Fig. 3 Non-coiling of the coil because of mismatch between the too
large coil windings relative to the small vessel diameter. The coil is
therefore unsuitable for automated tracking. The arrows indicate two
coils that were unsuitable for tracking due to noncoiling:
137×112 mm (96×96 DPI)
Fig. 4 a Patient with a second primary NSCLC in the right lung,
after having undergone left pneumonectomy 5 years earlier for early
stage NSCLC. Surgical treatment was considered not feasible
because of the previous pneumonectomy. Conventional radiother-
apy, using large margins to take tumour motion into account, would
result in increased risk for lung toxicity. Considering the low forced
expiratory volume in 1 s of 1,090 ml (38% of predicted), percuta-
neous insertion of markers with its risk of pneumothorax was
considered potentially life-threatening. Endovascular markers were
placed (indicated by the arrow) and the patient was treated with
CyberKnife by using a total dose of 45 Gy (administered in three
treatment sessions). b Follow-up at 10 weeks. Showed complete
tumour response. Arrow indicates the coil without remaining
tumour): 84×76 mm (96×96 DPI)
1574in the pulmonary artery branches to further reduce the
complication rates of pulmonary infarction and pleural pain.
Smaller coils may also be inserted closer to the tumour
than larger coils. In our study, six coils could not be used as
the distance from the tumour was too large to guarantee a
synchronous motion. We used 4D CT to evaluate the
relationship between both motions. A coil-tumour distance
smaller than or approximating 40 mm was shown to be
adequate. The smallest coil-tumour distance to be found
unacceptable on 4D CT was 56 mm.
Based on our initial results, dedicated coils for marker
purposes are currently being designed in close collabora-
tion with the coil manufacturer. With this development we
may expect to increase the proportion of coils that can be
used during a CyberKnife treatment.
In conclusion, the vascular insertion of coils is a valuable
and safe method for marker implantation for lung tumours.
This alternative route for placement is also feasible
whenever percutaneous (or bronchoscopic) insertion of
markers is not possible or undesirable. As a result, many
more patients with lung tumours may now benefit from
high-dose high-precision radiotherapy with CyberKnife
(Fig. 4).
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